C4 Therapeutics (CCCC) Revenue Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Revenue Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 16.50% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 296.11% |
| 10 | C4 Therapeutics | 499.92 Mn | 246.25 Mn | - | 2.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.75% |
| Mar 31, 2026 | -15.00% |
| Dec 31, 2025 | 112.79% |
| Sep 30, 2025 | -26.90% |
| Jun 30, 2025 | -46.17% |
| Mar 31, 2025 | 138.17% |
| Dec 31, 2024 | 58.75% |
| Sep 30, 2024 | 38.75% |
| Jun 30, 2024 | 350.68% |
| Mar 31, 2024 | -19.15% |
| Dec 31, 2023 | 14.26% |
| Sep 30, 2023 | 63.93% |
| Jun 30, 2023 | -80.74% |
| Mar 31, 2023 | -50.89% |
| Dec 31, 2022 | -85.79% |
| Sep 30, 2022 | -20.54% |
| Jun 30, 2022 | 41.44% |
| Mar 31, 2022 | 3.07% |
| Dec 31, 2021 | 143.02% |
| Sep 30, 2021 | 0.63% |